Suven Life Sciences Limited
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candida… Read more
Suven Life Sciences Limited (SUVEN) - Net Assets
Latest net assets as of September 2025: ₹2.81 Billion INR
Based on the latest financial reports, Suven Life Sciences Limited (SUVEN) has net assets worth ₹2.81 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹3.37 Billion) and total liabilities (₹561.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹2.81 Billion |
| % of Total Assets | 83.36% |
| Annual Growth Rate | 1.53% |
| 5-Year Change | 1.83% |
| 10-Year Change | -81.53% |
| Growth Volatility | 73.46 |
Suven Life Sciences Limited - Net Assets Trend (2005–2025)
This chart illustrates how Suven Life Sciences Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Suven Life Sciences Limited (2005–2025)
The table below shows the annual net assets of Suven Life Sciences Limited from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹1.10 Billion | -59.27% |
| 2024-03-31 | ₹2.70 Billion | -28.05% |
| 2023-03-31 | ₹3.75 Billion | +290.37% |
| 2022-03-31 | ₹961.45 Million | -10.98% |
| 2021-03-31 | ₹1.08 Billion | -24.66% |
| 2020-03-31 | ₹1.43 Billion | -82.75% |
| 2019-03-31 | ₹8.31 Billion | +8.29% |
| 2018-03-31 | ₹7.67 Billion | +15.05% |
| 2017-03-31 | ₹6.67 Billion | +12.01% |
| 2016-03-31 | ₹5.95 Billion | +6.46% |
| 2015-03-31 | ₹5.59 Billion | +111.50% |
| 2014-03-31 | ₹2.64 Billion | +71.21% |
| 2013-03-31 | ₹1.54 Billion | +21.12% |
| 2012-03-31 | ₹1.28 Billion | +0.62% |
| 2011-03-31 | ₹1.27 Billion | +7.35% |
| 2010-03-31 | ₹1.18 Billion | +3.17% |
| 2009-03-31 | ₹1.14 Billion | +7.57% |
| 2008-03-31 | ₹1.06 Billion | +4.80% |
| 2007-03-31 | ₹1.02 Billion | +12.53% |
| 2006-03-31 | ₹902.12 Million | +11.12% |
| 2005-03-31 | ₹811.85 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Suven Life Sciences Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 600180054900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₹218.07 Million | 19.83% |
| Other Comprehensive Income | ₹420.71 Million | 38.25% |
| Other Components | ₹6.47 Billion | 588.05% |
| Total Equity | ₹1.10 Billion | 100.00% |
Suven Life Sciences Limited Competitors by Market Cap
The table below lists competitors of Suven Life Sciences Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ONWARD MEDICAL BV EO -12
F:63E
|
$101.06 Million |
|
Chen Full International Co Ltd
TWO:8383
|
$101.07 Million |
|
CSB Bancorp Inc
PINK:CSBB
|
$101.12 Million |
|
Ovid Therapeutics Inc
NASDAQ:OVID
|
$101.12 Million |
|
Steel Partners Holdings LP
NYSE:SPLP
|
$101.04 Million |
|
Omega Flex Inc
NASDAQ:OFLX
|
$101.01 Million |
|
Konya Cimento Sanayi AS
IS:KONYA
|
$100.99 Million |
|
HIL Limited
NSE:HIL
|
$100.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Suven Life Sciences Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,700,406,000 to 1,099,868,000, a change of -1,600,538,000 (-59.3%).
- Net loss of 1,607,450,000 reduced equity.
- Other comprehensive income increased equity by 7,511,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹-1.61 Billion | -146.15% |
| Other Comprehensive Income | ₹7.51 Million | +0.68% |
| Other Changes | ₹-599.00K | -0.05% |
| Total Change | ₹- | -59.27% |
Book Value vs Market Value Analysis
This analysis compares Suven Life Sciences Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 27.30x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 26.77x to 27.30x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | ₹5.13 | ₹137.38 | x |
| 2006-03-31 | ₹5.70 | ₹137.38 | x |
| 2007-03-31 | ₹6.42 | ₹137.38 | x |
| 2008-03-31 | ₹6.72 | ₹137.38 | x |
| 2009-03-31 | ₹7.23 | ₹137.38 | x |
| 2010-03-31 | ₹7.46 | ₹137.38 | x |
| 2011-03-31 | ₹8.01 | ₹137.38 | x |
| 2012-03-31 | ₹8.06 | ₹137.38 | x |
| 2013-03-31 | ₹9.76 | ₹137.38 | x |
| 2014-03-31 | ₹16.71 | ₹137.38 | x |
| 2015-03-31 | ₹35.35 | ₹137.38 | x |
| 2016-03-31 | ₹37.63 | ₹137.38 | x |
| 2017-03-31 | ₹42.16 | ₹137.38 | x |
| 2018-03-31 | ₹55.56 | ₹137.38 | x |
| 2019-03-31 | ₹60.16 | ₹137.38 | x |
| 2020-03-31 | ₹9.06 | ₹137.38 | x |
| 2021-03-31 | ₹6.83 | ₹137.38 | x |
| 2022-03-31 | ₹6.08 | ₹137.38 | x |
| 2023-03-31 | ₹23.72 | ₹137.38 | x |
| 2024-03-31 | ₹12.38 | ₹137.38 | x |
| 2025-03-31 | ₹5.03 | ₹137.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Suven Life Sciences Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -146.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2415.11%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.23x
- Recent ROE (-146.15%) is below the historical average (-12.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 2.96% | 3.63% | 0.49x | 1.67x | ₹-57.12 Million |
| 2006 | 7.08% | 7.09% | 0.63x | 1.59x | ₹-26.34 Million |
| 2007 | 11.10% | 9.95% | 0.65x | 1.71x | ₹11.12 Million |
| 2008 | 7.85% | 6.96% | 0.60x | 1.87x | ₹-22.86 Million |
| 2009 | 6.22% | 5.06% | 0.76x | 1.63x | ₹-43.22 Million |
| 2010 | 5.93% | 5.41% | 0.63x | 1.73x | ₹-48.05 Million |
| 2011 | 8.21% | 6.91% | 0.67x | 1.76x | ₹-22.74 Million |
| 2012 | 11.26% | 7.03% | 0.72x | 2.23x | ₹16.10 Million |
| 2013 | 19.97% | 11.96% | 0.77x | 2.16x | ₹153.94 Million |
| 2014 | 54.51% | 28.25% | 1.05x | 1.84x | ₹1.18 Billion |
| 2015 | 19.44% | 20.88% | 0.67x | 1.38x | ₹528.19 Million |
| 2016 | 11.21% | 13.36% | 0.64x | 1.32x | ₹71.93 Million |
| 2017 | 13.07% | 16.04% | 0.67x | 1.22x | ₹204.87 Million |
| 2018 | 16.12% | 20.19% | 0.67x | 1.19x | ₹469.47 Million |
| 2019 | 10.46% | 13.47% | 0.62x | 1.25x | ₹38.44 Million |
| 2020 | -65.73% | -653.62% | 0.08x | 1.27x | ₹-1.09 Billion |
| 2021 | -66.80% | -535.31% | 0.10x | 1.19x | ₹-829.52 Million |
| 2022 | -126.89% | -1029.99% | 0.11x | 1.12x | ₹-1.32 Billion |
| 2023 | -31.51% | -873.52% | 0.03x | 1.04x | ₹-1.56 Billion |
| 2024 | -38.91% | -898.63% | 0.04x | 1.06x | ₹-1.32 Billion |
| 2025 | -146.15% | -2415.11% | 0.05x | 1.23x | ₹-1.72 Billion |
Industry Comparison
This section compares Suven Life Sciences Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Suven Life Sciences Limited (SUVEN) | ₹2.81 Billion | 2.96% | 0.20x | $101.05 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |